Dopaminergic neurons of the post-commissural putamen

Dopaminergic neuron loss in the post-commissural putamen represents the primary pathological substrate for motor dysfunction in Parkinson's disease (PD). The post-commissural putamen is the specific subregion of the striatum that undergoes the most severe and earliest dopamine depletion, often exceeding 80% loss by the time clinical symptoms manifest (Kish et al., 1988, PMID: 3367010). This loss disrupts the basal ganglia circuitry, specifically the motor loop, leading to symptoms such as bradykinesia and rigidity. While this is an anatomical and cellular target rather than a single molecule, it is the functional site for dopamine replacement therapies like Levodopa and dopamine agonists (StatPearls, NBK470193). Furthermore, the integrity of these neurons is a critical diagnostic marker, visualized through Ioflupane (123I) SPECT imaging, which targets the dopamine transporter (DAT) on these terminals (Politis, 2014, PMID: 24339113). Therapeutic research often focuses on neuroprotective agents intended to halt the degeneration of these specific neurons. Consequently, monitoring the density of these neurons serves as a primary endpoint for assessing disease progression and treatment efficacy in clinical trials.

Other names

Post-commissural putaminal dopamine terminalsStriatal dopaminergic innervationDopamine depletion in the putamen

Pharmacological agents act by increasing synaptic dopamine levels, directly stimulating postsynaptic dopamine receptors, or preventing the degradation of dopamine within the striatal environment to compensate for the loss of presynaptic terminals (StatPearls, NBK470193).